Cargando…

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan

BACKGROUND: Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations. OBJECTIVES: Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adalimumab, ustekinumab and secukinumab) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yu-Chen, Huang, Yi-Ting, Yang, Chao-Chun, Lai, Edward Chia-Cheng, Liu, Cheng-Han, Hsu, Chao-Kai, Wong, Tak-Wah, Chao, Sheau-Chiou, Sheu, Hamm-Ming, Lee, Chaw-Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771674/ https://www.ncbi.nlm.nih.gov/pubmed/33373425 http://dx.doi.org/10.1371/journal.pone.0244620

Ejemplares similares

Early Intervention with High-Dose Steroid Pulse Therapy Prolongs Disease-Free Interval of Severe Alopecia Areata: A Retrospective Study
por: Yang, Chao-Chun, et al.
Publicado: (2013)

Scleritis and anterior uveitis may herald the development of an epibulbar tumor in patients with extranodal Rosai-Dorfman disease: a case report
por: Lee, Yu-Kuei, et al.
Publicado: (2019)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
por: Baker, Erica L., et al.
Publicado: (2012)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Emergence of Vibrio cholerae O1 Sequence Type 75 in Taiwan
por: Tu, Yueh-Hua, et al.
Publicado: (2020)

Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasis
por: Cruz, Criselda Jean G., et al.
Publicado: (2023)

Sorafenib-Induced Eruptive Melanocytic Lesions
por: Chen, Hui-Chun, et al.
Publicado: (2021)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
por: Kowalzick, Lutz
Publicado: (2009)

Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis
por: Prieto-Pérez, Rocío, et al.
Publicado: (2015)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Gaps in moderate plaque psoriasis management: A survey of Saudi dermatologists
por: Almohideb, Mohammad, et al.
Publicado: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
por: Malara, Giovanna, et al.
Publicado: (2021)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “Treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland
por: Owczarek, Witold, et al.
Publicado: (2021)

Plan and Then Act: The Moderated Moderation Effects of Profession Identity and Action Control for Students at Arts Universities during the Career Development Process
por: Chen, Chia-Cheng, et al.
Publicado: (2022)

Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Guselkumab for plaque psoriasis
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jv10qli2m95kr6rvqarc1bvh1h